{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:10:15Z","timestamp":1792735815567,"version":"4.5.0"},"reference-count":162,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Aromatase inhibitor (AI)\u2013induced arthralgia (AIA) can lead to treatment discontinuation and worse disease outcomes. This study assessed the prevalence of AIA, nonadherence to AI therapy, and supportive care strategies (SCS) among patients with early-stage breast cancer.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Patients with early-stage breast cancer treated with adjuvant AI therapy were included from the CANTO cohort. AIA was defined as any-grade articular or muscular pain (CTCAE version 4.0) at years 1, 2, 4, and 6 after diagnosis (corresponding to 3\u20136 months, 1, 3, and 5 years of AI exposure, respectively). We assessed nonadherence to AI therapy, defined as any interruption and\/or discontinuation of AI. We evaluated the use of nonpharmacologic SCS, including meeting physical activity recommendations (\u226510 metabolic equivalent task hours per week [MET-h\/week]) and consultations with physical therapists, manual osteopaths, or acupuncturists, as well as pharmacologic SCS, including duloxetine use and AI switching. Multivariable logistic regression models were used to test associations among reported AIA, self-reported nonadherence to AI therapy, and SCS use.\n                    <jats:bold>Results:<\/jats:bold>\n                    Among 4,854 postmenopausal patients, 85.9% reported AIA at least once, including 68.5% at year 2 and 65.4% at year 4. Nonadherence to AI therapy was reported by 18.4% of patients with AIA compared with 6.8% of those without AIA (adjusted odds ratio [aOR], 2.35; 95% CI, 1.51\u20133.64), whereas permanent discontinuation was reported by 14.1% versus 3.4%, respectively. Subsequent physical therapy was consistently more frequent in patients reporting AIA (42.2% vs 31.2% at year 4; 37.8% vs 29.2% at year 6). The aOR for consulting physical therapists among patients reporting AIA at year 2 was 1.40 (95% CI,1.13\u20131.74). In contrast, other nonpharmacologic SCS use was not associated with reporting AIA. Switching AIs (19.7% vs 8.7%) was also associated with reporting AIA (aOR, 2.47; 95% CI, 1.59\u20133.83). Only 1.4% patients with AIA reported duloxetine use (vs 0.5%).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Although AIA was highly prevalent and associated with nonadherence to AI therapy among patients with early-stage breast cancer, uptake of recommended SCS was suboptimal and inconsistent. This study highlights gaps in guideline-concordant SCS implementation and underscores the need for efforts to maximize treatment retention during AI therapy.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7107","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:51:54Z","timestamp":1770735114000},"source":"Crossref","is-referenced-by-count":1,"title":["Aromatase Inhibitor\u2013Induced Arthralgia Among Patients With Early Breast Cancer: Prevalence, Treatment Nonadherence, and Management in a Prospective Longitudinal Cohort"],"prefix":"10.6004","volume":"24","author":[{"given":"Pietro","family":"Lapidari","sequence":"first","affiliation":[{"name":"University Paris Saclay, Gustave Roussy Institute, INSERM, Molecular Predictors and New Targets in Oncology, Cancer Survivorship Program, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam B.","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Havas","sequence":"additional","affiliation":[{"name":"University Paris Saclay, Gustave Roussy Institute, INSERM, Molecular Predictors and New Targets in Oncology, Cancer Survivorship Program, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pagliuca","sequence":"additional","affiliation":[{"name":"University Paris Saclay, Gustave Roussy Institute, INSERM, Molecular Predictors and New Targets in Oncology, Cancer Survivorship Program, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Franzoi","sequence":"additional","affiliation":[{"name":"University Paris Saclay, Gustave Roussy Institute, INSERM, Molecular Predictors and New Targets in Oncology, Cancer Survivorship Program, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenn","family":"Menvielle","sequence":"additional","affiliation":[{"name":"University Paris Saclay, Gustave Roussy Institute, INSERM, Molecular Predictors and New Targets in Oncology, Cancer Survivorship Program, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Jouannaud","sequence":"additional","affiliation":[{"name":"Medical Oncology, Jean Godinot Cancer Institute, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Sauterey","sequence":"additional","affiliation":[{"name":"Medical Oncology, ICO Institut de Cancerologie de l\u2019Ouest, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[{"name":"Medical Oncology, Centre Leon Berard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Cottu","sequence":"additional","affiliation":[{"name":"Medical Oncology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cherifi","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Centre Fran\u00e7ois Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lerebours","sequence":"additional","affiliation":[{"name":"Medical Oncology, Institut Curie, Saint Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gaudin","sequence":"additional","affiliation":[{"name":"Data and Partnerships Department, Unicancer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Martin","sequence":"additional","affiliation":[{"name":"Data and Partnerships Department, Unicancer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Vaz-Luis","sequence":"additional","affiliation":[{"name":"University Paris Saclay, Gustave Roussy Institute, INSERM, Molecular Predictors and New Targets in Oncology, Cancer Survivorship Program, Villejuif, France"},{"name":"Interdisciplinary Department for the Organization of Patient Pathways (DIOPP), Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Meglio","sequence":"additional","affiliation":[{"name":"University Paris Saclay, Gustave Roussy Institute, INSERM, Molecular Predictors and New Targets in Oncology, Cancer Survivorship Program, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Expert Rev Anticancer Ther","first-page":"1101","article-title":"Managing side effects in adjuvant endocrine therapy for breast cancer","volume":"18","author":"Condorelli R","year":"2018","unstructured":"Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther 2018;18:1101\u20131112."},{"key":"B2","series-title":"Lancet","first-page":"1341","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341\u20131352."},{"key":"B3","series-title":"N Engl J Med","first-page":"122","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis PA","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF,  Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122\u2013137."},{"key":"B4","series-title":"J Clin Oncol","first-page":"3877","article-title":"Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer","volume":"25","author":"Crew KD","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J,  Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877\u20133883."},{"key":"B5","series-title":"Breast Cancer Res Treat","first-page":"365","article-title":"Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors","volume":"111","author":"Henry NL","year":"2008","unstructured":"Henry NL, Giles JT, Ang D,  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008;111:365\u2013372."},{"key":"B6","series-title":"JCO Oncol Pract","first-page":"733","article-title":"Management of aromatase inhibitor-induced musculoskeletal symptoms","volume":"16","author":"Gupta A","year":"2020","unstructured":"Gupta A, Henry NL, Loprinzi CL. Management of aromatase inhibitor-induced musculoskeletal symptoms. JCO Oncol Pract 2020;16:733\u2013739."},{"key":"B7","article-title":"NCCN Clinical Practice Guidelines in Oncology: Survivorship. Version 2.2024","author":"Sanft T","unstructured":"Sanft T, Day AT, Ansbaugh SM,  NCCN Clinical Practice Guidelines in Oncology: Survivorship. Version 2.2024. Accessed May 2, 2024. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B8","series-title":"J Clin Oncol","first-page":"2452","article-title":"Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence","volume":"34","author":"Chirgwin JH","year":"2016","unstructured":"Chirgwin JH, Giobbie-Hurder A, Coates AS,  Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 2016;34:2452\u20132459."},{"key":"B9","series-title":"J Clin Oncol","first-page":"2762","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli B","year":"2020","unstructured":"Pistilli B, Paci A, Ferreira AR,  Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol 2020;38:2762\u20132772."},{"key":"B10","series-title":"J Breast Cancer","first-page":"309","article-title":"Investigation of factors affecting adherence to adjuvant hormone therapy in early-stage breast cancer patients: a comprehensive systematic review","volume":"26","author":"Yang S","year":"2023","unstructured":"Yang S, Park SW, Bae SJ,  Investigation of factors affecting adherence to adjuvant hormone therapy in early-stage breast cancer patients: a comprehensive systematic review. J Breast Cancer 2023;26:309\u2013333."},{"key":"B11","series-title":"J Clin Oncol","first-page":"4120","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman DL","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T,  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120\u20134128."},{"key":"B12","series-title":"J Clin Oncol","first-page":"2198","article-title":"Cancer survivors\u2019 adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society\u2019s SCS-II","volume":"26","author":"Blanchard CM","year":"2008","unstructured":"Blanchard CM, Courneya KS, Stein K. Cancer survivors\u2019 adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society\u2019s SCS-II. J Clin Oncol 2008;26:2198\u20132204."},{"key":"B13","series-title":"Med Sci Sports Exerc","first-page":"1484","article-title":"Physical activity levels among breast cancer survivors","volume":"36","author":"Irwin ML","year":"2004","unstructured":"Irwin ML, McTiernan A, Bernstein L,  Physical activity levels among breast cancer survivors. Med Sci Sports Exerc 2004;36:1484\u20131491."},{"key":"B14","article-title":"Common Terminology Criteria for Adverse Events (CTCAE)","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Accessed October 2, 2025. Available at: https:\/\/www.cancer.gov\/research\/resources\/resource\/210"},{"key":"B15","unstructured":"European Organisation for Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 Scoring Manual. Accessed April 9, 2024. Available at: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf"},{"key":"B16","article-title":"Breast Cancer (update of QLQ-BR23)","unstructured":"European Organisation for Research and Treatment of Cancer (EORTC). Breast Cancer (update of QLQ-BR23). Accessed July 29, 2025. Available at: https:\/\/qol.eortc.org\/questionnaire\/update-qlq-br23"},{"key":"B17","unstructured":"World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. Accessed April 9, 2024. Available at: https:\/\/www.who.int\/docs\/default-source\/ncds\/ncd-surveillance\/gpaq-analysis-guide.pdf"},{"key":"B18","series-title":"Acta Psychiatr Scand","first-page":"361","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond AS","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361\u2013370."},{"key":"B19","series-title":"ESMO Open","first-page":"e000562","article-title":"UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)","volume":"4","author":"Vaz-Luis I","year":"2019","unstructured":"Vaz-Luis I, Cottu P, Mesleard C,  UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open 2019;4:e000562."},{"key":"B20","series-title":"J Pain Symptom Manage","first-page":"1083","article-title":"Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review","volume":"45","author":"Oldenmenger WH","year":"2013","unstructured":"Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CCD. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage 2013;45:1083\u20131093."},{"key":"B21","series-title":"Health Qual Life Outcomes","first-page":"87","article-title":"Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain","volume":"14","author":"Giesinger JM","year":"2016","unstructured":"Giesinger JM, Kuijpers W, Young T,  Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes 2016;14:87."},{"key":"B22","series-title":"J Clin Epidemiol","first-page":"1","article-title":"Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research","volume":"118","author":"Giesinger JM","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK,  Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 2020;118:1\u20138."},{"key":"B23","series-title":"Oncologist","first-page":"e722","article-title":"The EORTC QLQ\u2010C30 summary score as prognostic factor for survival of patients with cancer in the \u201creal\u2010world\u201d: results from the population\u2010based PROFILES registry","volume":"25","author":"Husson O","year":"2020","unstructured":"Husson O, de Rooij BH, Kieffer J,  The EORTC QLQ\u2010C30 summary score as prognostic factor for survival of patients with cancer in the \u201creal\u2010world\u201d: results from the population\u2010based PROFILES registry. Oncologist 2020;25:e722\u2013732."},{"key":"B24","series-title":"Ann Oncol","first-page":"1443","article-title":"Aromatase inhibitor-induced arthralgia: a review","volume":"24","author":"Niravath P","year":"2013","unstructured":"Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 2013;24:1443\u20131449."},{"key":"B25","series-title":"Clin Breast Cancer","first-page":"39","article-title":"A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases","volume":"9","author":"Campos SM","year":"2009","unstructured":"Campos SM, Guastalla JP, Subar M,  A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009;9:39\u201344."},{"key":"B26","series-title":"Eur J Cancer","first-page":"2318","article-title":"An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole","volume":"39","author":"Rose C","year":"2003","unstructured":"Rose C, Vtoraya O, Pluzanska A,  An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318\u20132327."},{"key":"B27","series-title":"Clin Breast Cancer","first-page":"775","article-title":"Aromatase inhibitor-associated arthralgia and\/or bone pain: frequency and characterization in non-clinical trial patients","volume":"7","author":"Presant CA","year":"2007","unstructured":"Presant CA, Bosserman L, Young T,  Aromatase inhibitor-associated arthralgia and\/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007;7:775\u2013778."},{"key":"B28","series-title":"J Natl Cancer Inst","first-page":"1099","article-title":"Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation","volume":"115","author":"Balazard F","year":"2023","unstructured":"Balazard F, Bertaut A, Bordet \u00c9,  Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation. J Natl Cancer Inst 2023;115:1099\u20131108."},{"key":"B29","series-title":"J Clin Oncol","first-page":"936","article-title":"Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer","volume":"30","author":"Henry NL","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z,  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012;30:936\u2013942."},{"key":"B30","series-title":"PLoS One","first-page":"e81677","article-title":"Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer","volume":"8","author":"Huiart L","year":"2013","unstructured":"Huiart L, Bouhnik AD, Rey D,  Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS One 2013;8:e81677."},{"key":"B31","series-title":"BMC Cancer","first-page":"401","article-title":"Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors","volume":"13","author":"Chim K","year":"2013","unstructured":"Chim K, Xie SX, Stricker CT,  Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 2013;13:401."},{"key":"B32","series-title":"Breast Cancer Res","first-page":"89","article-title":"Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?","volume":"17","author":"Bauml J","year":"2015","unstructured":"Bauml J, Chen L, Chen J,  Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Breast Cancer Res 2015;17:89."},{"key":"B33","series-title":"Endocr Rev","first-page":"90","article-title":"Changes in proinflammatory cytokine activity after menopause","volume":"23","author":"Pfeilschifter J","year":"2002","unstructured":"Pfeilschifter J, K\u00f6ditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90\u2013119."},{"key":"B34","series-title":"Steroids","first-page":"749","article-title":"Aromatase in synovial cells from postmenopausal women","volume":"66","author":"Le Bail J","year":"2001","unstructured":"Le Bail J, Liagre B, Vergne P,  Aromatase in synovial cells from postmenopausal women. Steroids 2001;66:749\u2013757."},{"key":"B35","series-title":"Cancer Med","first-page":"240","article-title":"Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm","volume":"7","author":"Reinbolt RE","year":"2018","unstructured":"Reinbolt RE, Sonis S, Timmers CD,  Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. Cancer Med 2018;7:240\u2013253."},{"key":"B36","series-title":"J Clin Oncol","first-page":"12003","article-title":"Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: results from ECOG-ACRIN E1Z11","volume":"39","author":"Stearns V","year":"2021","unstructured":"Stearns V, Jegede O, Chang V,  Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: results from ECOG-ACRIN E1Z11. J Clin Oncol 2021;39(Suppl):Abstract 12003."},{"key":"B37","series-title":"Eur J Cancer","first-page":"31","article-title":"Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients","volume":"56","author":"Lintermans A","year":"2016","unstructured":"Lintermans A, Van Asten K, Jongen L,  Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. Eur J Cancer 2016;56:31\u201336."},{"key":"B38","series-title":"Support Care Cancer","first-page":"1587","article-title":"The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis","volume":"28","author":"Lu G","year":"2020","unstructured":"Lu G, Zheng J, Zhang L. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis. Support Care Cancer 2020;28:1587\u20131596."},{"key":"B39","series-title":"PM R","first-page":"1406","article-title":"The role of exercise in aromatase inhibitor-induced arthralgia","volume":"16","author":"Yu K","year":"2024","unstructured":"Yu K, Portes P, Morris GS,  The role of exercise in aromatase inhibitor-induced arthralgia. PM R 2024;16:1406\u20131416."},{"key":"B40","series-title":"J Geriatr Oncol","first-page":"148","article-title":"Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy","volume":"5","author":"Nyrop KA","year":"2014","unstructured":"Nyrop KA, Muss HB, Hackney B,  Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy. J Geriatr Oncol 2014;5:148\u2013155."},{"key":"B41","series-title":"Oncologist","first-page":"1238","article-title":"Randomized controlled trial of a home-based walking program to reduce moderate to severe aromatase inhibitor-associated arthralgia in breast cancer survivors","volume":"22","author":"Nyrop KA","year":"2017","unstructured":"Nyrop KA, Callahan LF, Cleveland RJ,  Randomized controlled trial of a home-based walking program to reduce moderate to severe aromatase inhibitor-associated arthralgia in breast cancer survivors. Oncologist 2017;22:1238\u20131249."},{"key":"B42","series-title":"J Pain Symptom Manage","first-page":"548","article-title":"Nordic walking as an exercise intervention to reduce pain in women with aromatase inhibitor-associated arthralgia: a feasibility study","volume":"52","author":"Fields J","year":"2016","unstructured":"Fields J, Richardson A, Hopkinson J, Fenlon D. Nordic walking as an exercise intervention to reduce pain in women with aromatase inhibitor-associated arthralgia: a feasibility study. J Pain Symptom Manage 2016;52:548\u2013559."},{"key":"B43","series-title":"J Clin Oncol","first-page":"1104","article-title":"Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors","volume":"33","author":"Irwin ML","year":"2015","unstructured":"Irwin ML, Cartmel B, Gross CP,  Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015;33:1104\u20131111."},{"key":"B44","series-title":"Eur J Cancer Care (Engl)","first-page":"493","article-title":"Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study","volume":"23","author":"DeNysschen CA","year":"2014","unstructured":"DeNysschen CA, Burton H, Ademuyiwa F,  Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. Eur J Cancer Care (Engl) 2014;23:493\u2013501."},{"key":"B45","series-title":"Integr Cancer Ther","first-page":"313","article-title":"Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias","volume":"11","author":"Galantino ML","year":"2012","unstructured":"Galantino ML, Desai K, Greene L,  Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther 2012;11:313\u2013320."},{"key":"B46","series-title":"Psychooncology","first-page":"1578","article-title":"Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer","volume":"24","author":"Jacobsen PB","year":"2015","unstructured":"Jacobsen PB, Muchnick S, Marcus S,  Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer. Psychooncology 2015;24:1578\u20131580."},{"key":"B47","series-title":"J Natl Compr Canc Netw","article-title":"Uptake of recommendations for posttreatment cancer-related fatigue among breast cancer survivors","volume":"19","author":"Di Meglio A","year":"2021","unstructured":"Di Meglio A, Charles C, Martin E,  Uptake of recommendations for posttreatment cancer-related fatigue among breast cancer survivors. J Natl Compr Canc Netw 2021;19:98\u2013110."},{"key":"B48","series-title":"Cancer","first-page":"2774","article-title":"Unhealthy behaviors after breast cancer: capitalizing on a teachable moment to promote lifestyle improvements","volume":"127","author":"Di Meglio A","year":"2021","unstructured":"Di Meglio A, Gbenou AS, Martin E,  Unhealthy behaviors after breast cancer: capitalizing on a teachable moment to promote lifestyle improvements. Cancer 2021;127:2774\u20132787."},{"key":"B49","article-title":"Activit\u00e9 physique et s\u00e9dentarit\u00e9 dans la population fran\u00e7aise. Situation en 2014\u20132016 et \u00e9volution depuis 2006\u20132007","author":"Verdot C","unstructured":"Verdot C, Salanave B, Deschamps V. Activit\u00e9 physique et s\u00e9dentarit\u00e9 dans la population fran\u00e7aise. Situation en 2014\u20132016 et \u00e9volution depuis 2006\u20132007. Accessed October 17, 2024. Available at: http:\/\/beh.santepubliquefrance.fr\/beh\/2020\/15\/2020_15_1.html"},{"key":"B50","series-title":"Breast J","first-page":"22","article-title":"Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors","volume":"20","author":"Brown JC","year":"2014","unstructured":"Brown JC, Mao JJ, Stricker C,  Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J 2014;20:22\u201328."},{"key":"B51","article-title":"Tableaux r\u00e9capitulatifs des taux de remboursement","unstructured":"l\u2019Assurance Maladie. Tableaux r\u00e9capitulatifs des taux de remboursement. Accessed October 17, 2024. Available at: https:\/\/www.ameli.fr\/paris\/assure\/remboursements\/rembourse\/tableau-recapitulatif-taux-remboursement"},{"key":"B52","article-title":"Les affections de longue dur\u00e9e exon\u00e9rantes","unstructured":"l\u2019Assurance Maladie. Les affections de longue dur\u00e9e exon\u00e9rantes. Accessed October 17, 2024. Available at: https:\/\/www.ameli.fr\/paris\/masseur-kinesitherapeute\/exercice-liberal\/prescription-prise-charge\/prise-charge-situation-patient\/situation-patient-ald-exonerantes"},{"key":"B53","article-title":"URPS Kin\u00e9 \u00cele-de-France","unstructured":"URPS Kin\u00e9 \u00cele-de-France. S\u00e9nologie: les r\u00f4les du Kin\u00e9 dans l\u2019accompagnement des personnes atteintes d\u2019un cancer du sein. Accessed October 17, 2024. Available at: https:\/\/www.urps-kine-idf.com\/blog\/octobre-rose-mettons-en-lumiere-le-role-du-kine-dans-la-prise- en-charge-du-cancer-du-sein"},{"key":"B54","series-title":"PM R","first-page":"S317","article-title":"The underutilization of rehabilitation to treat physical impairments in breast cancer survivors","volume":"9","author":"Stubblefield MD","year":"2017","unstructured":"Stubblefield MD. The underutilization of rehabilitation to treat physical impairments in breast cancer survivors. PM R 2017;9:S317\u2013323."},{"key":"B55","series-title":"JAMA","first-page":"167","article-title":"Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial","volume":"320","author":"Hershman DL","year":"2018","unstructured":"Hershman DL, Unger JM, Greenlee H,  Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA 2018;320:167\u2013176."},{"key":"B56","series-title":"J Clin Oncol","first-page":"1154","article-title":"Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer","volume":"28","author":"Crew KD","year":"2010","unstructured":"Crew KD, Capodice JL, Greenlee H,  Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2010;28:1154\u20131160."},{"key":"B57","series-title":"Integr Cancer Ther","first-page":"854","article-title":"Barriers to acupuncture use among breast cancer survivors: a cross-sectional analysis","volume":"17","author":"Bao T","year":"2018","unstructured":"Bao T, Li Q, DeRito JL,  Barriers to acupuncture use among breast cancer survivors: a cross-sectional analysis. Integr Cancer Ther 2018;17:854\u2013859."},{"key":"B58","series-title":"Med Law Int","first-page":"235","article-title":"The regulation of acupuncture in France and the UK: shifts and fragmentation in contrasting healthcare systems","volume":"19","author":"Cloatre E","year":"2019","unstructured":"Cloatre E, Ramas FS. The regulation of acupuncture in France and the UK: shifts and fragmentation in contrasting healthcare systems. Med Law Int 2019;19:235\u2013257."},{"key":"B59","series-title":"J Clin Oncol","first-page":"326","article-title":"Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202","volume":"36","author":"Henry NL","year":"2018","unstructured":"Henry NL, Unger JM, Schott AF,  Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol 2018;36:326\u2013332."},{"key":"B60","series-title":"JNCI Cancer Spectr","first-page":"pkab018","article-title":"Adverse events and perception of benefit from duloxetine for treating aromatase inhibitor-associated arthralgias","volume":"5","author":"Schnell PM","year":"2021","unstructured":"Schnell PM, Lustberg MB, Henry NL. Adverse events and perception of benefit from duloxetine for treating aromatase inhibitor-associated arthralgias. JNCI Cancer Spectr 2021;5:pkab018."},{"key":"B61","series-title":"Int J Clin Pharmacol Ther","first-page":"1","article-title":"Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions","volume":"52","author":"Augendre-Ferrante B","year":"2014","unstructured":"Augendre-Ferrante B, Picard H, Evans D,  Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions. Int J Clin Pharmacol Ther 2014;52:1\u20137."},{"key":"B62","series-title":"Breast Cancer Res Treat","first-page":"127","article-title":"Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study","volume":"120","author":"Briot K","year":"2010","unstructured":"Briot K, Tubiana-Hulin M, Bastit L,  Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010;120:127\u2013134."},{"key":"B63","series-title":"J Clin Oncol","first-page":"2647","article-title":"Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline","volume":"36","author":"Lyman GH","year":"2018","unstructured":"Lyman GH, Greenlee H, Bohlke K,  Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol 2018;36:2647\u20132655."},{"key":"B64","series-title":"Breast Cancer Res Treat","first-page":"517","article-title":"Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue","volume":"190","author":"Lapidari P","year":"2021","unstructured":"Lapidari P, Djehal N, Havas J,  Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue. Breast Cancer Res Treat 2021;190:517\u2013529."},{"key":"B65","article-title":"D\u00e9remboursement des m\u00e9dicaments hom\u00e9opathiques","unstructured":"Government Information Service (SIG). D\u00e9remboursement des m\u00e9dicaments hom\u00e9opathiques. Accessed July 18, 2024. Available at: https:\/\/www.info.gouv.fr\/actualite\/deremboursement-des-medicaments-homeopathiques"},{"key":"B66","series-title":"J Altern Complement Med","first-page":"347","article-title":"The health beliefs and behaviors of three groups of complementary medicine and a general practice group of patients","volume":"1","author":"Furnham A","year":"1995","unstructured":"Furnham A, Vincent C, Wood R. The health beliefs and behaviors of three groups of complementary medicine and a general practice group of patients. J Altern Complement Med 1995;1:347\u2013359."},{"key":"B67","series-title":"Wien Klin Wochenschr","first-page":"232","article-title":"Against all odds\u2013the persistent popularity of homeopathy","volume":"132","author":"Cukaci C","year":"2020","unstructured":"Cukaci C, Freissmuth M, Mann C,  Against all odds\u2013the persistent popularity of homeopathy. Wien Klin Wochenschr 2020;132:232\u2013242."},{"key":"B68","series-title":"Cancer Med","first-page":"e71117","article-title":"Pilot study of cannabidiol for treatment of aromatase inhibitor\u2010associated musculoskeletal symptoms in breast cancer","volume":"14","author":"Fleege NMG","year":"2025","unstructured":"Fleege NMG, Miller EA, Kidwell KM,  Pilot study of cannabidiol for treatment of aromatase inhibitor\u2010associated musculoskeletal symptoms in breast cancer. Cancer Med 2025;14:e71117."},{"key":"B69","series-title":"J Clin Oncol","first-page":"1575","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline","volume":"42","author":"Braun IM","year":"2024","unstructured":"Braun IM, Bohlke K, Abrams DI,  Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol 2024;42:1575\u20131593."},{"key":"B70","series-title":"J Clin Oncol","first-page":"3998","article-title":"Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline","volume":"40","author":"Mao JJ","year":"2022","unstructured":"Mao JJ, Ismaila N, Bao T,  Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline. J Clin Oncol 2022;40:3998\u20134024."},{"key":"B71","series-title":"J Cancer Surviv","first-page":"906","article-title":"Current practice patterns and gaps in guideline-concordant breast cancer survivorship care","volume":"17","author":"Brauer ER","year":"2023","unstructured":"Brauer ER, Long EF, Petersen L, Ganz PA. Current practice patterns and gaps in guideline-concordant breast cancer survivorship care. J Cancer Surviv 2023;17:906\u2013915."},{"key":"B72","series-title":"Lancet Oncol","first-page":"e30","article-title":"Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities","volume":"18","author":"Nekhlyudov L","year":"2017","unstructured":"Nekhlyudov L, O\u2019Malley DM, Hudson SV. Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities. Lancet Oncol 2017;18:e30\u201338."},{"key":"B73","series-title":"Support Care Cancer","first-page":"85","article-title":"Facilitators and barriers to shared primary and specialist cancer care: a systematic review","volume":"29","author":"Lisy K","year":"2021","unstructured":"Lisy K, Kent J, Piper A, Jefford M. Facilitators and barriers to shared primary and specialist cancer care: a systematic review. Support Care Cancer 2021;29:85\u201396."},{"key":"B74","series-title":"J Cancer Educ","first-page":"1219","article-title":"Primary care providers\u2019 knowledge, attitudes, beliefs, and practices regarding their preparedness to provide cancer survivorship care","volume":"35","author":"Geramita EM","year":"2020","unstructured":"Geramita EM, Parker IR, Brufsky JW,  Primary care providers\u2019 knowledge, attitudes, beliefs, and practices regarding their preparedness to provide cancer survivorship care. J Cancer Educ 2020;35:1219\u20131226."},{"key":"B75","series-title":"JCO Oncol Pract","first-page":"e1249","article-title":"Survivorship care plans: reaching a benchmark and striving to achieve intent","volume":"16","author":"Stuver R","year":"2020","unstructured":"Stuver R, Faig J, Cadorette M,  Survivorship care plans: reaching a benchmark and striving to achieve intent. JCO Oncol Pract 2020;16:e1249\u20131254."},{"key":"B76","series-title":"Oncol Res Treat","first-page":"504","article-title":"A systematic review for evaluation of specialized programs for addressing young women with breast cancer problems","volume":"45","author":"Abedian Kasgri K","year":"2022","unstructured":"Abedian Kasgri K, Abazari M, Tehrani H,  A systematic review for evaluation of specialized programs for addressing young women with breast cancer problems. Oncol Res Treat 2022;45:504\u2013524."},{"key":"B77","series-title":"ESMO Open","first-page":"102236","article-title":"Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes","volume":"9","author":"Franzoi MA","year":"2024","unstructured":"Franzoi MA, Aupomerol M, Havas J,  Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes. ESMO Open 2024;9:102236."},{"key":"B78","series-title":"Lancet","first-page":"1551","article-title":"Improved models of care for cancer survivors","volume":"399","author":"Jefford M","year":"2022","unstructured":"Jefford M, Howell D, Li Q,  Improved models of care for cancer survivors. Lancet 2022;399:1551\u20131560."},{"key":"B79","series-title":"JMIR Res Protoc","first-page":"e52841","article-title":"Evaluating the implementation of integrated proactive supportive care pathways in oncology: master protocol for a cohort study","volume":"13","author":"Franzoi MA","year":"2024","unstructured":"Franzoi MA, Pages A, Papageorgiou L,  Evaluating the implementation of integrated proactive supportive care pathways in oncology: master protocol for a cohort study. JMIR Res Protoc 2024;13:e52841."},{"key":"B80","series-title":"JCO Oncol Pract","first-page":"353","article-title":"Implementing a PROACTive care pathway to empower and support survivors of breast cancer","volume":"19","author":"Franzoi MA","year":"2023","unstructured":"Franzoi MA, Degous\u00e9e L, Martin E,  Implementing a PROACTive care pathway to empower and support survivors of breast cancer. JCO Oncol Pract 2023;19:353\u2013361."},{"key":"B81","series-title":"J Clin Epidemiol","first-page":"267","article-title":"Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects","volume":"67","author":"McCambridge J","year":"2014","unstructured":"McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014;67:267\u2013277."},{"key":"B1","series-title":"Expert Rev Anticancer Ther","first-page":"1101","article-title":"Managing side effects in adjuvant endocrine therapy for breast cancer","volume":"18","author":"Condorelli R","year":"2018","unstructured":"Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther 2018;18:1101\u20131112."},{"key":"B2","series-title":"Lancet","first-page":"1341","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341\u20131352."},{"key":"B3","series-title":"N Engl J Med","first-page":"122","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis PA","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF,  Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122\u2013137."},{"key":"B4","series-title":"J Clin Oncol","first-page":"3877","article-title":"Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer","volume":"25","author":"Crew KD","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J,  Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877\u20133883."},{"key":"B5","series-title":"Breast Cancer Res Treat","first-page":"365","article-title":"Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors","volume":"111","author":"Henry NL","year":"2008","unstructured":"Henry NL, Giles JT, Ang D,  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008;111:365\u2013372."},{"key":"B6","series-title":"JCO Oncol Pract","first-page":"733","article-title":"Management of aromatase inhibitor-induced musculoskeletal symptoms","volume":"16","author":"Gupta A","year":"2020","unstructured":"Gupta A, Henry NL, Loprinzi CL. Management of aromatase inhibitor-induced musculoskeletal symptoms. JCO Oncol Pract 2020;16:733\u2013739."},{"key":"B7","article-title":"NCCN Clinical Practice Guidelines in Oncology: Survivorship. Version 2.2024","author":"Sanft T","unstructured":"Sanft T, Day AT, Ansbaugh SM,  NCCN Clinical Practice Guidelines in Oncology: Survivorship. Version 2.2024. Accessed May 2, 2024. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B8","series-title":"J Clin Oncol","first-page":"2452","article-title":"Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence","volume":"34","author":"Chirgwin JH","year":"2016","unstructured":"Chirgwin JH, Giobbie-Hurder A, Coates AS,  Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 2016;34:2452\u20132459."},{"key":"B9","series-title":"J Clin Oncol","first-page":"2762","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli B","year":"2020","unstructured":"Pistilli B, Paci A, Ferreira AR,  Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol 2020;38:2762\u20132772."},{"key":"B10","series-title":"J Breast Cancer","first-page":"309","article-title":"Investigation of factors affecting adherence to adjuvant hormone therapy in early-stage breast cancer patients: a comprehensive systematic review","volume":"26","author":"Yang S","year":"2023","unstructured":"Yang S, Park SW, Bae SJ,  Investigation of factors affecting adherence to adjuvant hormone therapy in early-stage breast cancer patients: a comprehensive systematic review. J Breast Cancer 2023;26:309\u2013333."},{"key":"B11","series-title":"J Clin Oncol","first-page":"4120","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman DL","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T,  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120\u20134128."},{"key":"B12","series-title":"J Clin Oncol","first-page":"2198","article-title":"Cancer survivors\u2019 adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society\u2019s SCS-II","volume":"26","author":"Blanchard CM","year":"2008","unstructured":"Blanchard CM, Courneya KS, Stein K. Cancer survivors\u2019 adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society\u2019s SCS-II. J Clin Oncol 2008;26:2198\u20132204."},{"key":"B13","series-title":"Med Sci Sports Exerc","first-page":"1484","article-title":"Physical activity levels among breast cancer survivors","volume":"36","author":"Irwin ML","year":"2004","unstructured":"Irwin ML, McTiernan A, Bernstein L,  Physical activity levels among breast cancer survivors. Med Sci Sports Exerc 2004;36:1484\u20131491."},{"key":"B14","article-title":"Common Terminology Criteria for Adverse Events (CTCAE)","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Accessed October 2, 2025. Available at: https:\/\/www.cancer.gov\/research\/resources\/resource\/210"},{"key":"B15","unstructured":"European Organisation for Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 Scoring Manual. Accessed April 9, 2024. Available at: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf"},{"key":"B16","article-title":"Breast Cancer (update of QLQ-BR23)","unstructured":"European Organisation for Research and Treatment of Cancer (EORTC). Breast Cancer (update of QLQ-BR23). Accessed July 29, 2025. Available at: https:\/\/qol.eortc.org\/questionnaire\/update-qlq-br23"},{"key":"B17","unstructured":"World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. Accessed April 9, 2024. Available at: https:\/\/www.who.int\/docs\/default-source\/ncds\/ncd-surveillance\/gpaq-analysis-guide.pdf"},{"key":"B18","series-title":"Acta Psychiatr Scand","first-page":"361","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond AS","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361\u2013370."},{"key":"B19","series-title":"ESMO Open","first-page":"e000562","article-title":"UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)","volume":"4","author":"Vaz-Luis I","year":"2019","unstructured":"Vaz-Luis I, Cottu P, Mesleard C,  UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open 2019;4:e000562."},{"key":"B20","series-title":"J Pain Symptom Manage","first-page":"1083","article-title":"Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review","volume":"45","author":"Oldenmenger WH","year":"2013","unstructured":"Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CCD. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage 2013;45:1083\u20131093."},{"key":"B21","series-title":"Health Qual Life Outcomes","first-page":"87","article-title":"Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain","volume":"14","author":"Giesinger JM","year":"2016","unstructured":"Giesinger JM, Kuijpers W, Young T,  Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes 2016;14:87."},{"key":"B22","series-title":"J Clin Epidemiol","first-page":"1","article-title":"Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research","volume":"118","author":"Giesinger JM","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK,  Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 2020;118:1\u20138."},{"key":"B23","series-title":"Oncologist","first-page":"e722","article-title":"The EORTC QLQ\u2010C30 summary score as prognostic factor for survival of patients with cancer in the \u201creal\u2010world\u201d: results from the population\u2010based PROFILES registry","volume":"25","author":"Husson O","year":"2020","unstructured":"Husson O, de Rooij BH, Kieffer J,  The EORTC QLQ\u2010C30 summary score as prognostic factor for survival of patients with cancer in the \u201creal\u2010world\u201d: results from the population\u2010based PROFILES registry. Oncologist 2020;25:e722\u2013732."},{"key":"B24","series-title":"Ann Oncol","first-page":"1443","article-title":"Aromatase inhibitor-induced arthralgia: a review","volume":"24","author":"Niravath P","year":"2013","unstructured":"Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 2013;24:1443\u20131449."},{"key":"B25","series-title":"Clin Breast Cancer","first-page":"39","article-title":"A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases","volume":"9","author":"Campos SM","year":"2009","unstructured":"Campos SM, Guastalla JP, Subar M,  A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009;9:39\u201344."},{"key":"B26","series-title":"Eur J Cancer","first-page":"2318","article-title":"An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole","volume":"39","author":"Rose C","year":"2003","unstructured":"Rose C, Vtoraya O, Pluzanska A,  An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318\u20132327."},{"key":"B27","series-title":"Clin Breast Cancer","first-page":"775","article-title":"Aromatase inhibitor-associated arthralgia and\/or bone pain: frequency and characterization in non-clinical trial patients","volume":"7","author":"Presant CA","year":"2007","unstructured":"Presant CA, Bosserman L, Young T,  Aromatase inhibitor-associated arthralgia and\/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007;7:775\u2013778."},{"key":"B28","series-title":"J Natl Cancer Inst","first-page":"1099","article-title":"Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation","volume":"115","author":"Balazard F","year":"2023","unstructured":"Balazard F, Bertaut A, Bordet \u00c9,  Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation. J Natl Cancer Inst 2023;115:1099\u20131108."},{"key":"B29","series-title":"J Clin Oncol","first-page":"936","article-title":"Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer","volume":"30","author":"Henry NL","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z,  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012;30:936\u2013942."},{"key":"B30","series-title":"PLoS One","first-page":"e81677","article-title":"Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer","volume":"8","author":"Huiart L","year":"2013","unstructured":"Huiart L, Bouhnik AD, Rey D,  Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS One 2013;8:e81677."},{"key":"B31","series-title":"BMC Cancer","first-page":"401","article-title":"Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors","volume":"13","author":"Chim K","year":"2013","unstructured":"Chim K, Xie SX, Stricker CT,  Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 2013;13:401."},{"key":"B32","series-title":"Breast Cancer Res","first-page":"89","article-title":"Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?","volume":"17","author":"Bauml J","year":"2015","unstructured":"Bauml J, Chen L, Chen J,  Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Breast Cancer Res 2015;17:89."},{"key":"B33","series-title":"Endocr Rev","first-page":"90","article-title":"Changes in proinflammatory cytokine activity after menopause","volume":"23","author":"Pfeilschifter J","year":"2002","unstructured":"Pfeilschifter J, K\u00f6ditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90\u2013119."},{"key":"B34","series-title":"Steroids","first-page":"749","article-title":"Aromatase in synovial cells from postmenopausal women","volume":"66","author":"Le Bail J","year":"2001","unstructured":"Le Bail J, Liagre B, Vergne P,  Aromatase in synovial cells from postmenopausal women. Steroids 2001;66:749\u2013757."},{"key":"B35","series-title":"Cancer Med","first-page":"240","article-title":"Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm","volume":"7","author":"Reinbolt RE","year":"2018","unstructured":"Reinbolt RE, Sonis S, Timmers CD,  Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. Cancer Med 2018;7:240\u2013253."},{"key":"B36","series-title":"J Clin Oncol","first-page":"12003","article-title":"Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: results from ECOG-ACRIN E1Z11","volume":"39","author":"Stearns V","year":"2021","unstructured":"Stearns V, Jegede O, Chang V,  Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: results from ECOG-ACRIN E1Z11. J Clin Oncol 2021;39(Suppl):Abstract 12003."},{"key":"B37","series-title":"Eur J Cancer","first-page":"31","article-title":"Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients","volume":"56","author":"Lintermans A","year":"2016","unstructured":"Lintermans A, Van Asten K, Jongen L,  Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. Eur J Cancer 2016;56:31\u201336."},{"key":"B38","series-title":"Support Care Cancer","first-page":"1587","article-title":"The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis","volume":"28","author":"Lu G","year":"2020","unstructured":"Lu G, Zheng J, Zhang L. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors: a systematic review and meta-analysis. Support Care Cancer 2020;28:1587\u20131596."},{"key":"B39","series-title":"PM R","first-page":"1406","article-title":"The role of exercise in aromatase inhibitor-induced arthralgia","volume":"16","author":"Yu K","year":"2024","unstructured":"Yu K, Portes P, Morris GS,  The role of exercise in aromatase inhibitor-induced arthralgia. PM R 2024;16:1406\u20131416."},{"key":"B40","series-title":"J Geriatr Oncol","first-page":"148","article-title":"Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy","volume":"5","author":"Nyrop KA","year":"2014","unstructured":"Nyrop KA, Muss HB, Hackney B,  Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy. J Geriatr Oncol 2014;5:148\u2013155."},{"key":"B41","series-title":"Oncologist","first-page":"1238","article-title":"Randomized controlled trial of a home-based walking program to reduce moderate to severe aromatase inhibitor-associated arthralgia in breast cancer survivors","volume":"22","author":"Nyrop KA","year":"2017","unstructured":"Nyrop KA, Callahan LF, Cleveland RJ,  Randomized controlled trial of a home-based walking program to reduce moderate to severe aromatase inhibitor-associated arthralgia in breast cancer survivors. Oncologist 2017;22:1238\u20131249."},{"key":"B42","series-title":"J Pain Symptom Manage","first-page":"548","article-title":"Nordic walking as an exercise intervention to reduce pain in women with aromatase inhibitor-associated arthralgia: a feasibility study","volume":"52","author":"Fields J","year":"2016","unstructured":"Fields J, Richardson A, Hopkinson J, Fenlon D. Nordic walking as an exercise intervention to reduce pain in women with aromatase inhibitor-associated arthralgia: a feasibility study. J Pain Symptom Manage 2016;52:548\u2013559."},{"key":"B43","series-title":"J Clin Oncol","first-page":"1104","article-title":"Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors","volume":"33","author":"Irwin ML","year":"2015","unstructured":"Irwin ML, Cartmel B, Gross CP,  Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015;33:1104\u20131111."},{"key":"B44","series-title":"Eur J Cancer Care (Engl)","first-page":"493","article-title":"Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study","volume":"23","author":"DeNysschen CA","year":"2014","unstructured":"DeNysschen CA, Burton H, Ademuyiwa F,  Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. Eur J Cancer Care (Engl) 2014;23:493\u2013501."},{"key":"B45","series-title":"Integr Cancer Ther","first-page":"313","article-title":"Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias","volume":"11","author":"Galantino ML","year":"2012","unstructured":"Galantino ML, Desai K, Greene L,  Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther 2012;11:313\u2013320."},{"key":"B46","series-title":"Psychooncology","first-page":"1578","article-title":"Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer","volume":"24","author":"Jacobsen PB","year":"2015","unstructured":"Jacobsen PB, Muchnick S, Marcus S,  Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer. Psychooncology 2015;24:1578\u20131580."},{"key":"B47","series-title":"J Natl Compr Canc Netw","article-title":"Uptake of recommendations for posttreatment cancer-related fatigue among breast cancer survivors","volume":"19","author":"Di Meglio A","year":"2021","unstructured":"Di Meglio A, Charles C, Martin E,  Uptake of recommendations for posttreatment cancer-related fatigue among breast cancer survivors. J Natl Compr Canc Netw 2021;19:98\u2013110."},{"key":"B48","series-title":"Cancer","first-page":"2774","article-title":"Unhealthy behaviors after breast cancer: capitalizing on a teachable moment to promote lifestyle improvements","volume":"127","author":"Di Meglio A","year":"2021","unstructured":"Di Meglio A, Gbenou AS, Martin E,  Unhealthy behaviors after breast cancer: capitalizing on a teachable moment to promote lifestyle improvements. Cancer 2021;127:2774\u20132787."},{"key":"B49","article-title":"Activit\u00e9 physique et s\u00e9dentarit\u00e9 dans la population fran\u00e7aise. Situation en 2014\u20132016 et \u00e9volution depuis 2006\u20132007","author":"Verdot C","unstructured":"Verdot C, Salanave B, Deschamps V. Activit\u00e9 physique et s\u00e9dentarit\u00e9 dans la population fran\u00e7aise. Situation en 2014\u20132016 et \u00e9volution depuis 2006\u20132007. Accessed October 17, 2024. Available at: http:\/\/beh.santepubliquefrance.fr\/beh\/2020\/15\/2020_15_1.html"},{"key":"B50","series-title":"Breast J","first-page":"22","article-title":"Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors","volume":"20","author":"Brown JC","year":"2014","unstructured":"Brown JC, Mao JJ, Stricker C,  Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J 2014;20:22\u201328."},{"key":"B51","article-title":"Tableaux r\u00e9capitulatifs des taux de remboursement","unstructured":"l\u2019Assurance Maladie. Tableaux r\u00e9capitulatifs des taux de remboursement. Accessed October 17, 2024. Available at: https:\/\/www.ameli.fr\/paris\/assure\/remboursements\/rembourse\/tableau-recapitulatif-taux-remboursement"},{"key":"B52","article-title":"Les affections de longue dur\u00e9e exon\u00e9rantes","unstructured":"l\u2019Assurance Maladie. Les affections de longue dur\u00e9e exon\u00e9rantes. Accessed October 17, 2024. Available at: https:\/\/www.ameli.fr\/paris\/masseur-kinesitherapeute\/exercice-liberal\/prescription-prise-charge\/prise-charge-situation-patient\/situation-patient-ald-exonerantes"},{"key":"B53","article-title":"URPS Kin\u00e9 \u00cele-de-France","unstructured":"URPS Kin\u00e9 \u00cele-de-France. S\u00e9nologie: les r\u00f4les du Kin\u00e9 dans l\u2019accompagnement des personnes atteintes d\u2019un cancer du sein. Accessed October 17, 2024. Available at: https:\/\/www.urps-kine-idf.com\/blog\/octobre-rose-mettons-en-lumiere-le-role-du-kine-dans-la-prise- en-charge-du-cancer-du-sein"},{"key":"B54","series-title":"PM R","first-page":"S317","article-title":"The underutilization of rehabilitation to treat physical impairments in breast cancer survivors","volume":"9","author":"Stubblefield MD","year":"2017","unstructured":"Stubblefield MD. The underutilization of rehabilitation to treat physical impairments in breast cancer survivors. PM R 2017;9:S317\u2013323."},{"key":"B55","series-title":"JAMA","first-page":"167","article-title":"Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial","volume":"320","author":"Hershman DL","year":"2018","unstructured":"Hershman DL, Unger JM, Greenlee H,  Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA 2018;320:167\u2013176."},{"key":"B56","series-title":"J Clin Oncol","first-page":"1154","article-title":"Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer","volume":"28","author":"Crew KD","year":"2010","unstructured":"Crew KD, Capodice JL, Greenlee H,  Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2010;28:1154\u20131160."},{"key":"B57","series-title":"Integr Cancer Ther","first-page":"854","article-title":"Barriers to acupuncture use among breast cancer survivors: a cross-sectional analysis","volume":"17","author":"Bao T","year":"2018","unstructured":"Bao T, Li Q, DeRito JL,  Barriers to acupuncture use among breast cancer survivors: a cross-sectional analysis. Integr Cancer Ther 2018;17:854\u2013859."},{"key":"B58","series-title":"Med Law Int","first-page":"235","article-title":"The regulation of acupuncture in France and the UK: shifts and fragmentation in contrasting healthcare systems","volume":"19","author":"Cloatre E","year":"2019","unstructured":"Cloatre E, Ramas FS. The regulation of acupuncture in France and the UK: shifts and fragmentation in contrasting healthcare systems. Med Law Int 2019;19:235\u2013257."},{"key":"B59","series-title":"J Clin Oncol","first-page":"326","article-title":"Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202","volume":"36","author":"Henry NL","year":"2018","unstructured":"Henry NL, Unger JM, Schott AF,  Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol 2018;36:326\u2013332."},{"key":"B60","series-title":"JNCI Cancer Spectr","first-page":"pkab018","article-title":"Adverse events and perception of benefit from duloxetine for treating aromatase inhibitor-associated arthralgias","volume":"5","author":"Schnell PM","year":"2021","unstructured":"Schnell PM, Lustberg MB, Henry NL. Adverse events and perception of benefit from duloxetine for treating aromatase inhibitor-associated arthralgias. JNCI Cancer Spectr 2021;5:pkab018."},{"key":"B61","series-title":"Int J Clin Pharmacol Ther","first-page":"1","article-title":"Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions","volume":"52","author":"Augendre-Ferrante B","year":"2014","unstructured":"Augendre-Ferrante B, Picard H, Evans D,  Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions. Int J Clin Pharmacol Ther 2014;52:1\u20137."},{"key":"B62","series-title":"Breast Cancer Res Treat","first-page":"127","article-title":"Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study","volume":"120","author":"Briot K","year":"2010","unstructured":"Briot K, Tubiana-Hulin M, Bastit L,  Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010;120:127\u2013134."},{"key":"B63","series-title":"J Clin Oncol","first-page":"2647","article-title":"Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline","volume":"36","author":"Lyman GH","year":"2018","unstructured":"Lyman GH, Greenlee H, Bohlke K,  Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol 2018;36:2647\u20132655."},{"key":"B64","series-title":"Breast Cancer Res Treat","first-page":"517","article-title":"Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue","volume":"190","author":"Lapidari P","year":"2021","unstructured":"Lapidari P, Djehal N, Havas J,  Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue. Breast Cancer Res Treat 2021;190:517\u2013529."},{"key":"B65","article-title":"D\u00e9remboursement des m\u00e9dicaments hom\u00e9opathiques","unstructured":"Government Information Service (SIG). D\u00e9remboursement des m\u00e9dicaments hom\u00e9opathiques. Accessed July 18, 2024. Available at: https:\/\/www.info.gouv.fr\/actualite\/deremboursement-des-medicaments-homeopathiques"},{"key":"B66","series-title":"J Altern Complement Med","first-page":"347","article-title":"The health beliefs and behaviors of three groups of complementary medicine and a general practice group of patients","volume":"1","author":"Furnham A","year":"1995","unstructured":"Furnham A, Vincent C, Wood R. The health beliefs and behaviors of three groups of complementary medicine and a general practice group of patients. J Altern Complement Med 1995;1:347\u2013359."},{"key":"B67","series-title":"Wien Klin Wochenschr","first-page":"232","article-title":"Against all odds\u2013the persistent popularity of homeopathy","volume":"132","author":"Cukaci C","year":"2020","unstructured":"Cukaci C, Freissmuth M, Mann C,  Against all odds\u2013the persistent popularity of homeopathy. Wien Klin Wochenschr 2020;132:232\u2013242."},{"key":"B68","series-title":"Cancer Med","first-page":"e71117","article-title":"Pilot study of cannabidiol for treatment of aromatase inhibitor\u2010associated musculoskeletal symptoms in breast cancer","volume":"14","author":"Fleege NMG","year":"2025","unstructured":"Fleege NMG, Miller EA, Kidwell KM,  Pilot study of cannabidiol for treatment of aromatase inhibitor\u2010associated musculoskeletal symptoms in breast cancer. Cancer Med 2025;14:e71117."},{"key":"B69","series-title":"J Clin Oncol","first-page":"1575","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline","volume":"42","author":"Braun IM","year":"2024","unstructured":"Braun IM, Bohlke K, Abrams DI,  Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol 2024;42:1575\u20131593."},{"key":"B70","series-title":"J Clin Oncol","first-page":"3998","article-title":"Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline","volume":"40","author":"Mao JJ","year":"2022","unstructured":"Mao JJ, Ismaila N, Bao T,  Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline. J Clin Oncol 2022;40:3998\u20134024."},{"key":"B71","series-title":"J Cancer Surviv","first-page":"906","article-title":"Current practice patterns and gaps in guideline-concordant breast cancer survivorship care","volume":"17","author":"Brauer ER","year":"2023","unstructured":"Brauer ER, Long EF, Petersen L, Ganz PA. Current practice patterns and gaps in guideline-concordant breast cancer survivorship care. J Cancer Surviv 2023;17:906\u2013915."},{"key":"B72","series-title":"Lancet Oncol","first-page":"e30","article-title":"Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities","volume":"18","author":"Nekhlyudov L","year":"2017","unstructured":"Nekhlyudov L, O\u2019Malley DM, Hudson SV. Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities. Lancet Oncol 2017;18:e30\u201338."},{"key":"B73","series-title":"Support Care Cancer","first-page":"85","article-title":"Facilitators and barriers to shared primary and specialist cancer care: a systematic review","volume":"29","author":"Lisy K","year":"2021","unstructured":"Lisy K, Kent J, Piper A, Jefford M. Facilitators and barriers to shared primary and specialist cancer care: a systematic review. Support Care Cancer 2021;29:85\u201396."},{"key":"B74","series-title":"J Cancer Educ","first-page":"1219","article-title":"Primary care providers\u2019 knowledge, attitudes, beliefs, and practices regarding their preparedness to provide cancer survivorship care","volume":"35","author":"Geramita EM","year":"2020","unstructured":"Geramita EM, Parker IR, Brufsky JW,  Primary care providers\u2019 knowledge, attitudes, beliefs, and practices regarding their preparedness to provide cancer survivorship care. J Cancer Educ 2020;35:1219\u20131226."},{"key":"B75","series-title":"JCO Oncol Pract","first-page":"e1249","article-title":"Survivorship care plans: reaching a benchmark and striving to achieve intent","volume":"16","author":"Stuver R","year":"2020","unstructured":"Stuver R, Faig J, Cadorette M,  Survivorship care plans: reaching a benchmark and striving to achieve intent. JCO Oncol Pract 2020;16:e1249\u20131254."},{"key":"B76","series-title":"Oncol Res Treat","first-page":"504","article-title":"A systematic review for evaluation of specialized programs for addressing young women with breast cancer problems","volume":"45","author":"Abedian Kasgri K","year":"2022","unstructured":"Abedian Kasgri K, Abazari M, Tehrani H,  A systematic review for evaluation of specialized programs for addressing young women with breast cancer problems. Oncol Res Treat 2022;45:504\u2013524."},{"key":"B77","series-title":"ESMO Open","first-page":"102236","article-title":"Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes","volume":"9","author":"Franzoi MA","year":"2024","unstructured":"Franzoi MA, Aupomerol M, Havas J,  Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes. ESMO Open 2024;9:102236."},{"key":"B78","series-title":"Lancet","first-page":"1551","article-title":"Improved models of care for cancer survivors","volume":"399","author":"Jefford M","year":"2022","unstructured":"Jefford M, Howell D, Li Q,  Improved models of care for cancer survivors. Lancet 2022;399:1551\u20131560."},{"key":"B79","series-title":"JMIR Res Protoc","first-page":"e52841","article-title":"Evaluating the implementation of integrated proactive supportive care pathways in oncology: master protocol for a cohort study","volume":"13","author":"Franzoi MA","year":"2024","unstructured":"Franzoi MA, Pages A, Papageorgiou L,  Evaluating the implementation of integrated proactive supportive care pathways in oncology: master protocol for a cohort study. JMIR Res Protoc 2024;13:e52841."},{"key":"B80","series-title":"JCO Oncol Pract","first-page":"353","article-title":"Implementing a PROACTive care pathway to empower and support survivors of breast cancer","volume":"19","author":"Franzoi MA","year":"2023","unstructured":"Franzoi MA, Degous\u00e9e L, Martin E,  Implementing a PROACTive care pathway to empower and support survivors of breast cancer. JCO Oncol Pract 2023;19:353\u2013361."},{"key":"B81","series-title":"J Clin Epidemiol","first-page":"267","article-title":"Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects","volume":"67","author":"McCambridge J","year":"2014","unstructured":"McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014;67:267\u2013277."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e257107.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e257107.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e257107.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:26Z","timestamp":1773318686000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e257107.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":162,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7107","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}